CV Sciences, Inc.: insider trades · United States · SEC (Form 4)

About CV Sciences, Inc.

CV Sciences, Inc. is a U.S.-listed consumer wellness company traded on the OTCQB under the symbol CVSI, which is relevant for investors tracking SEC Form 4 insider activity. While not listed on NYSE or NASDAQ, the company is still a U.S. public issuer with regular SEC reporting and a small-cap profile. It is based in San Diego, California, in the United States, and was originally incorporated in December 2010 as Foreclosure Solutions, Inc. before evolving through corporate restructuring and a name change into CV Sciences. Its principal offices and facilities are in San Diego, with additional operations in Grand Junction, Colorado, and Warsaw, Poland. CV Sciences’ core business is centered on wellness products, hemp extracts, natural ingredients, and plant-based foods. The company develops, manufactures, markets, and distributes hemp-derived CBD products and other science-backed natural ingredients through both B2B and B2C channels. Its flagship brand, +PlusCBD™, launched in 2014, is positioned as a leading hemp-extract brand in the natural products retail market and includes products such as softgels, tinctures, topicals, and gummies. The company also sells +PlusHLTH™, Cultured Foods™, and Lunar Fox™, extending its reach into nutraceuticals, beauty care, specialty foods, and pet products. In addition, CV Sciences owns Elevated Softgels, a manufacturer of softgels and tinctures for the supplement and nutrition industry. From a competitive standpoint, CV Sciences operates in a crowded and highly regulated niche. It is a small-cap company with limited scale versus large consumer health and nutraceutical peers, but it benefits from a differentiated scientific positioning, a recognizable hemp-derived brand in +PlusCBD™, and a broader product portfolio than many pure-play CBD companies. The company says it currently manufactures and distributes more than 50 products across four brands, supporting a more diversified revenue mix. Its acquisition of Cultured Foods in Poland also adds an international dimension, giving it exposure to plant-based foods and supplement distribution in Europe. Recent developments have been centered on operational improvement and product refresh rather than aggressive top-line expansion. In fiscal 2025, CV Sciences reported sales of $13.8 million, down 12.2% year over year, but management highlighted stronger margins, lower operating expenses, and positive adjusted EBITDA in the fourth quarter of 2025. The company also launched 39 new products since January 1, 2023, with 39% of 2025 net revenue coming from those newer launches. A notable recent product addition was Ignite, a men’s performance formula under the +PlusCBD™ line. For investors, the equity remains a turnaround-style story: progress on profitability is encouraging, but the business is still exposed to U.S. hemp/CBD regulation, supply-chain execution, and the challenge of sustaining growth in a competitive wellness market.